Compare Stocks: PVLA, KYMR, PCVX, and APGE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$134.84 +0.3%	$119.35	$34.34 ▼ $134.88	$8.34B	0.34	1.16 million shs	1.50 million shs
KYMR Kymera Therapeutics	$107.52 +1.0%	$101.31	$36.65 ▼ $130.05	$8.94B	1.95	570,274 shs	463,571 shs
PCVX Vaxcyte	$58.07 -1.4%	$53.85	$29.29 ▼ $65.00	$8.39B	1.23	938,993 shs	1.30 million shs
PVLA Palvella Therapeutics	$157.77 +1.8%	$133.76	$38.95 ▼ $161.38	$2.27B	-0.17	211,951 shs	182,299 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	0.00%	+0.56%	+0.95%	+62.40%	+268.49%
KYMR Kymera Therapeutics	0.00%	+3.98%	-9.65%	+24.91%	+160.02%
PCVX Vaxcyte	0.00%	+7.38%	-2.94%	+9.55%	+75.97%
PVLA Palvella Therapeutics	0.00%	+13.47%	+4.46%	+30.08%	+303.81%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$134.84 +0.3%	$119.35	$34.34 ▼ $134.88	$8.34B	0.34	1.16 million shs	1.50 million shs
KYMR Kymera Therapeutics	$107.52 +1.0%	$101.31	$36.65 ▼ $130.05	$8.94B	1.95	570,274 shs	463,571 shs
PCVX Vaxcyte	$58.07 -1.4%	$53.85	$29.29 ▼ $65.00	$8.39B	1.23	938,993 shs	1.30 million shs
PVLA Palvella Therapeutics	$157.77 +1.8%	$133.76	$38.95 ▼ $161.38	$2.27B	-0.17	211,951 shs	182,299 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	0.00%	+0.56%	+0.95%	+62.40%	+268.49%
KYMR Kymera Therapeutics	0.00%	+3.98%	-9.65%	+24.91%	+160.02%
PCVX Vaxcyte	0.00%	+7.38%	-2.94%	+9.55%	+75.97%
PVLA Palvella Therapeutics	0.00%	+13.47%	+4.46%	+30.08%	+303.81%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APGE Apogee Therapeutics	2.24	Hold	$121.25	-10.08% Downside
KYMR Kymera Therapeutics	2.83	Moderate Buy	$125.65	16.86% Upside
PCVX Vaxcyte	2.38	Hold	$86.00	48.10% Upside
PVLA Palvella Therapeutics	3.00	Buy	$209.14	32.56% Upside

Current Analyst Ratings Breakdown

Latest PVLA, KYMR, PCVX, and APGE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2026	KYMR Kymera Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$135.00
8/6/2026	KYMR Kymera Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/6/2026	KYMR Kymera Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$133.00 ➝ $139.00
8/5/2026	KYMR Kymera Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$125.00
8/5/2026	PVLA Palvella Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$207.00
8/5/2026	PVLA Palvella Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$232.00
7/30/2026	KYMR Kymera Therapeutics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold	$120.00
7/28/2026	KYMR Kymera Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$125.00 ➝ $135.00
7/28/2026	PVLA Palvella Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/22/2026	PVLA Palvella Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$270.00
7/17/2026	APGE Apogee Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	$13.23 per share	N/A
KYMR Kymera Therapeutics	$39.21M	228.01	N/A	N/A	$19.42 per share	5.54
PCVX Vaxcyte	N/A	N/A	N/A	N/A	$19.10 per share	N/A
PVLA Palvella Therapeutics	$42.81M	53.11	N/A	N/A	$15.05 per share	10.48

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APGE Apogee Therapeutics	-$255.84M	-$4.33	N/A	N/A	N/A	N/A	-32.64%	-31.25%	8/10/2026 (Estimated)
KYMR Kymera Therapeutics	-$311.35M	-$3.57	N/A	N/A	N/A	-285.33%	-21.82%	-19.66%	N/A
PCVX Vaxcyte	-$766.63M	-$7.63	N/A	N/A	N/A	N/A	-37.56%	-33.62%	N/A
PVLA Palvella Therapeutics	-$41.72M	-$4.83	N/A	N/A	N/A	N/A	-47.84%	-38.33%	N/A

Latest PVLA, KYMR, PCVX, and APGE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	APGE Apogee Therapeutics	-$1.07	N/A	N/A	N/A	$10.00 million	N/A
8/5/2026	Q2 2026	KYMR Kymera Therapeutics	-$0.7126	-$0.62	+$0.0926	-$0.62	$32.78 million	$65.00 million
8/5/2026	Q2 2026	PCVX Vaxcyte	-$2.06	-$1.97	+$0.09	-$1.97	$12.50 million	N/A
8/4/2026	Q2 2026	PVLA Palvella Therapeutics	-$1.17	-$1.52	-$0.35	-$1.52	N/A	N/A
5/11/2026	Q1 2026	APGE Apogee Therapeutics	-$1.0658	-$1.06	+$0.0058	-$1.06	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APGE Apogee Therapeutics	N/A	32.59	32.59
KYMR Kymera Therapeutics	N/A	10.81	10.81
PCVX Vaxcyte	N/A	5.72	7.49
PVLA Palvella Therapeutics	N/A	21.18	28.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APGE Apogee Therapeutics	79.04%
KYMR Kymera Therapeutics	N/A
PCVX Vaxcyte	96.78%
PVLA Palvella Therapeutics	40.11%

Insider Ownership

Company	Insider Ownership
APGE Apogee Therapeutics	24.30%
KYMR Kymera Therapeutics	15.98%
PCVX Vaxcyte	3.30%
PVLA Palvella Therapeutics	17.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APGE Apogee Therapeutics	91	61.88 million	46.84 million	Optionable
KYMR Kymera Therapeutics	170	83.15 million	69.86 million	Optionable
PCVX Vaxcyte	160	144.40 million	139.63 million	Optionable
PVLA Palvella Therapeutics	N/A	14.41 million	11.93 million	N/A

PVLA, KYMR, PCVX, and APGE Headlines

Recent News About These Companies

Palvella Therapeutics, Inc. $PVLA Shares Purchased by The Manufacturers Life Insurance Company

August 9 at 4:48 AM | marketbeat.com

HC Wainwright Issues Pessimistic Forecast for PVLA Earnings

August 9 at 1:14 AM | americanbankingnews.com

Is Palvella Therapeutics (PVLA) Fully Valued Ahead Of QTORIN Approval?

August 8 at 1:19 PM | finance.yahoo.com

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Consensus Rating of "Buy" from Analysts

August 7 at 6:28 AM | marketbeat.com

Q3 EPS Estimate for Palvella Therapeutics Cut by Analyst

August 7 at 6:11 AM | marketbeat.com

Palvella Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 5, 2026 | seekingalpha.com

Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

August 5, 2026 | globenewswire.com

Palvella Therapeutics Charts Clear Path From Data To Launch

August 4, 2026 | tipranks.com

Palvella Therapeutics, Inc. (PVLA) Q2 2026 Earnings Call Transcript

August 4, 2026 | seekingalpha.com

Full Transcript: Palvella Therapeutics Q2 2026 Earnings Call

August 4, 2026 | benzinga.com

Palvella Therapeutics Q2 Earnings Call Highlights

August 4, 2026 | marketbeat.com

Palvella Therapeutics (NASDAQ:PVLA) Posts Quarterly Earnings Results, Misses Expectations By $0.35 EPS

August 4, 2026 | marketbeat.com

Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 4, 2026 | globenewswire.com

Arete Wealth Advisors LLC Makes New $2.18 Million Investment in Palvella Therapeutics, Inc. $PVLA

August 1, 2026 | marketbeat.com

Palvella Therapeutics, Inc. $PVLA Shares Bought by Avidity Partners Management LP

August 1, 2026 | marketbeat.com

Chardan Capital Upgrades Palvella Therapeutics (NASDAQ:PVLA) to Strong-Buy

July 31, 2026 | marketbeat.com

Palvella Therapeutics (PVLA) Expected to Post Quarterly Earnings on Tuesday

July 30, 2026 | marketbeat.com

Palvella Therapeutics to Provide Public Comment at FDA Meeting on Drug Repurposing Criteria and Prioritization

July 30, 2026 | quiverquant.comQ

Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing

July 30, 2026 | globenewswire.com

Arete Wealth Advisors LLC Takes Position in Palvella Therapeutics, Inc. $PVLA

July 30, 2026 | marketbeat.com

Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update ...

July 28, 2026 | caledonianrecord.comC

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVLA, KYMR, PCVX, and APGE Company Descriptions

Apogee Therapeutics NASDAQ:APGE

$134.84 +0.35 (+0.26%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$134.84 0.00 (0.00%)

As of 08/7/2026 07:34 PM Eastern

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Kymera Therapeutics NASDAQ:KYMR

$107.52 +1.11 (+1.04%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$107.46 -0.06 (-0.06%)

As of 08/7/2026 07:34 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Vaxcyte NASDAQ:PCVX

$58.07 -0.82 (-1.39%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$58.06 -0.01 (-0.01%)

As of 08/7/2026 07:34 PM Eastern

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Palvella Therapeutics NASDAQ:PVLA

$157.77 +2.84 (+1.83%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$157.78 +0.01 (+0.01%)

As of 08/7/2026 07:34 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PVLA, KYMR, PCVX, and APGE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PVLA, KYMR, PCVX, and APGE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PVLA, KYMR, PCVX, and APGE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVLA, KYMR, PCVX, and APGE Company Descriptions

Apogee Therapeutics NASDAQ:APGE

Kymera Therapeutics NASDAQ:KYMR

Vaxcyte NASDAQ:PCVX

Palvella Therapeutics NASDAQ:PVLA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PVLA, KYMR, PCVX, and APGE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PVLA, KYMR, PCVX, and APGE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PVLA, KYMR, PCVX, and APGE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVLA, KYMR, PCVX, and APGE Company Descriptions

Apogee Therapeutics NASDAQ:APGE

Kymera Therapeutics NASDAQ:KYMR

Vaxcyte NASDAQ:PCVX

Palvella Therapeutics NASDAQ:PVLA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools